Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Senti Biosciences ( (SNTI) ) has issued an announcement.
Senti Biosciences reported encouraging initial results from a Phase 1 clinical trial of SENTI-202, an innovative CAR-NK cell therapy targeting hematologic malignancies like AML. Two out of three patients achieved complete remission at the initial dose, showing no detectable cancer cells, with the therapy being well-tolerated. The trial continues with dose escalation and further data expected in 2025, offering hope for patients with limited treatment options.
Find detailed analytics on SNTI stock on TipRanks’ Stock Analysis page.
